昭衍新药反弹逾6% 美国取消动物试验计划进展较缓慢 且与公司宗旨及发展一致

智通财经
14 Apr

昭衍新药(06127)反弹逾6%,截至发稿,涨5.09%,报10.74港元,成交额1.04亿港元。消息面上,4月10日,美国FDA在官网宣布,计划逐步取消单抗和其他药物的动物试验要求,转而使用包括基于人工智能的毒性计算模型、细胞系以及实验室环境下的类器官毒性测试等。昭衍新药公告称,相信该计划将在坚实的科学数据研究基础上逐步实施,推动行业加快替代研究的步伐,这一方向与公司的服务宗旨及发展规划保持一致...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10